Makers of generic Reglan liable for inadequate warning labels

December 21st, 2009 by Jennifer Walker-Journey

judge gavelMakers of generic drugs who do not adequately label their products to warn consumers of possible risks are not exempt from liability, according to a ruling by the U.S. Court of Appeals for the Eighth Circuit. The court ruled on a product liability lawsuit brought by Gladys Mensing, who was prescribed metoclopramide to treat diabetic gastroparesis, a debilitating condition in which the stomach empties too slowly. Following use of the medication, Mensing developed a serious movement disorder known as Tardive Dyskinesia. Research has shown that the condition can be caused by long-term use of . Mensing sued several makers of generic , known by the brand name Reglan, for not adequately warning consumers of the risk of developing the movement disorder.

Generic drug makers successfully argued in district court that a Food and Drug Administration  (FDA) regulation that required generic drugs to carry the same labels as their brand-name equivalents conflicted with the failure-to-warn claims. However, the Eighth Circuit Court overturned the dismissal resulting in a victory for Mensing.

It proved too late for Mensing, but earlier this year the FDA issued a for (), advising physicians to avoid long-term use of the drug except in rare cases where the benefit outweighs the risks. Long-term users and elderly patients, especially women, are at an increased risk for developing the serious movement disorder. There is no known cure for , even after the medication has been discontinued.

Patients currently taking or the generic should discuss any risks or side effects with their health care provider.

Related posts:

blog comments powered by Disqus

Comments are moderated and generally will be posted if they are on-topic and not abusive.